With this report, we demonstrate that the TAM receptors are a crucial therapeutic vulnerability in TNBC and treatment-resistant HER2+ breast cancer, the most important therapeutic challenges in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.